Decoding Cardiovascular Disease Biology

Decoding Cardiovascular Disease Biology

Decoding
Cardiovascular
Biology

CardiaTec is a TechBio company leveraging large scale multiomics data to discover novel cardiovascular therapeutics
We are building the largest human cardiac tissue multiomics database through our large hospital and academic network
Our company and technology was spun out of the Han Lab, University of Cambridge
01/03
Cardiovascular Disease is the world’s leading cause of death.
01/03
Our poor understanding of the complex biology of cardiovascular diseases has limited clinical translation and deterred investment:
Cardio
Oncology
Pipeline Growth 2015-19:
0%
0%
US R&D Spend 2016‑21:
$0B
$0B

Building and navigating large multiomic maps of human disease biology

Through the application of state-of-the-art computational modelling CardiaTec navigates high dimensional human tissue multiomics data to unravel the complex mechanisms driving disease progression. Our platform powers the discovery and development of novel therapeutics for cardiovascular diseases.
Proteomics
transcriptomics
Transcriptomics
epigenomics
Epigenomics
transcriptomics
Genomics

Proprietary Data Strategy

01/02

Team

Namshik Han
CTO & Co-founder
Thelma Zablocki
COO & Co-founder
Raphael Peralta
CEO & Co-founder
Woochang Hwang
Principal ML Scientist
Meabh MacMahon
Principal Data Scientist
Sara Ahrabi
Principal Target Discovery Scientist
Agata Rumianek
Associate Principal Cardiovascular Scientist
Franck Duclos
Director of Cardiovascular Science
Niall Santamaria
Board member
Diana Röttger
Board Member
Todd Kimmel
Board Member
Joseph Lehár
SAB Member
Dr Ian Dunham
SAB Member
Victor Dillard
SAB Member
Prof. Wilson Tang
SAB Member

News

CardiaTec’s story featured by TechCrunch

CardiaTec raises $6.5M in Seed funding, led by San Francisco-based Montage Ventures

CardiaTec honoured as the AI Startup of the Year at the East England StartUp Awards 2024

CardiaTec’s Co-Founders recognised Forbes 30 under 30

CardiaTec featured in the Guardian’s Health Awareness campaign

CardiaTec announced winners of the One to Watch at the Cambridge Independent Science & Technology Awards

CardiaTec listed in the AI-driven drug discovery startups to watch by Sifted

The story of our Co-Founder & CTO Prof. Namshik Han covered in Owkin’s “Humanity” book about AI augmented health

CardiaTec named in the 2023 Cofinitive Cambridge’s 21 to Watch

CardiaTec selected and successfully completes the KQ Labs Accelerator

Our Co-Founder & COO Thelma Zablocki shortlisted in Europe’s most exciting young founders

CardiaTec completes its £1.4M pre-seed fundraise

CardiaTec won the 2022 annual Bright SCIdea competition

Decoding
Cardiovascular
Biology

CardiaTec is a TechBio company leveraging large scale multiomics data to discover novel cardiovascular therapeutics
We are building the largest human cardiac tissue multiomics database through our large hospital and academic network
Our company and technology was spun out of the Han Lab, University of Cambridge
01/03
Cardiovascular Disease is the world’s leading cause of death.
01/03
Our poor understanding of the complex biology of cardiovascular diseases has limited clinical translation and deterred investment:
Cardio
Oncology
Pipeline Growth 2015-19:
0%
0%
US R&D Spend 2016‑21:
$0B
$0B

Building and navigating large multiomic maps of human disease biology

Through the application of state-of-the-art computational modelling CardiaTec navigates high dimensional human tissue multiomics data to unravel the complex mechanisms driving disease progression. Our platform powers the discovery and development of novel therapeutics for cardiovascular diseases.
Proteomics
transcriptomics
Transcriptomics
epigenomics
Epigenomics
transcriptomics
Genomics

Proprietary Data Strategy

01/02

Team

Namshik Han
CTO & Co-founder
Thelma Zablocki
COO & Co-founder
Raphael Peralta
CEO & Co-founder
Woochang Hwang
Principal ML Scientist
Meabh MacMahon
Principal Data Scientist
Sara Ahrabi
Principal Target Discovery Scientist
Agata Rumianek
Associate Principal Cardiovascular Scientist
Franck Duclos
Director of Cardiovascular Science
Niall Santamaria
Board member
Diana Röttger
Board Member
Todd Kimmel
Board Member
Joseph Lehár
SAB Member
Dr Ian Dunham
SAB Member
Victor Dillard
SAB Member
Prof. Wilson Tang
SAB Member

News

CardiaTec’s story featured by TechCrunch

CardiaTec raises $6.5M in Seed funding, led by San Francisco-based Montage Ventures

CardiaTec honoured as the AI Startup of the Year at the East England StartUp Awards 2024

CardiaTec’s Co-Founders recognised Forbes 30 under 30

CardiaTec featured in the Guardian’s Health Awareness campaign

CardiaTec announced winners of the One to Watch at the Cambridge Independent Science & Technology Awards

CardiaTec listed in the AI-driven drug discovery startups to watch by Sifted

The story of our Co-Founder & CTO Prof. Namshik Han covered in Owkin’s “Humanity” book about AI augmented health

CardiaTec named in the 2023 Cofinitive Cambridge’s 21 to Watch

CardiaTec selected and successfully completes the KQ Labs Accelerator

Our Co-Founder & COO Thelma Zablocki shortlisted in Europe’s most exciting young founders

CardiaTec completes its £1.4M pre-seed fundraise

CardiaTec won the 2022 annual Bright SCIdea competition